News

This year, ALLG achieved an increase in the number and participation of clinical trials, an increase in member engagement, and improved site commitment to the trial program. Thank you to all the [...]

The Australasian Leukaemia and Lymphoma Group (ALLG) held its November 2018 Scientific Meeting (SM) in Brisbane with 111 members in attendance.

The recent Blood 2018 meeting in Brisbane was definitely a highlight of this year. The ALLG had the opportunity to set up a display booth outlining our most recent clinical trials and to raise [...]

September is 'blood cancer awareness month', and we had the opportunity to take part in a number of conferences, workshops and summits to raise awareness of who we are and to promote our work in [...]

“If the study can confirm the benefit of a PET response adapted approach, it will establish a new standard of care for follicular lymphoma globally”, said A/Prof Trotman.

On Wednesday 25 July, Federal Health Minister Greg Hunt announced $3.2 million in funding to four clinical trials that will give adolescent and young adult cancer patients access to cutting-edge [...]

On Monday 11 June, the Chairman of the ALLG, Mr Peter T Kempen was announced as an honorary Member (AM) in the general division of the Order of Australia honours for significant service to the [...]

The Australasian Leukaemia and Lymphoma Group (ALLG) held its May 2018 Scientific Meeting (SM) in Melbourne with 270 members in attendance.

Late last year the ALLG welcomed the release of the Select Committee report into Funding for Research into Cancers with Low Survival Rates, calling on the Federal Government to make research into [...]

Professor Michael Pfreundschuh, one of the leading experts in the world of Lymphoma research and treatment, sadly passed away on March 5th 2018.

This year, almost 16,000 Australians will begin a long and gruelling journey with blood cancer. Decades of research have led to vastly improved outcomes for blood cancer patients with survival [...]

The Australasian Leukaemia & Lymphoma Group (ALLG) welcomed the November 2017 release of the Select Committee Report into funding for research into cancers with low survival rates.